https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Athersys%2C_Inc.Athersys, Inc. - Revizia istoricului2026-04-10T01:57:05ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Athersys,_Inc.&diff=407767&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Athersys, Inc. listata cu simbolurile US.ATHX, US.ATHXc ==Descriere companie== Athersys, Inc. (www.athersys.com) is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflamm...2024-09-18T13:39:47Z<p>Pagină nouă: Pagina dedicata companiei Athersys, Inc. listata cu simbolurile US.ATHX, US.ATHXc ==Descriere companie== Athersys, Inc. (www.athersys.com) is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflamm...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Athersys, Inc. listata cu simbolurile US.ATHX, US.ATHXc<br />
<br />
==Descriere companie==<br />
Athersys, Inc. (www.athersys.com) is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is a biologic product that is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The Company is conducting Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The Company's programs in the clinical development-stage include ischemic stroke, Acute respiratory distress syndrome (ARDS) and trauma.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ATHX" /><br />
<iframe key="tradeville" path="graficSimbol/US.ATHXc" /><br />
<br />
==Ultimele stiri despre Athersys, Inc. (US.ATHX)==<br />
<dynamicpagelist><br />
category=US.ATHX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
==Ultimele stiri despre Athersys, Inc. (US.ATHXc)==<br />
<dynamicpagelist><br />
category=US.ATHXc<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ATHX]][[Categorie:US.ATHXc]][[Categorie:Stiri despre companii]]</div>Admin